Low-renin hypertension (LRH) is a frequent condition in patients with arterial hypertension, accounting for 30% of patients. Monogenic forms can cause LRH in a minority of cases. However, in the large majority of patients, LRH is caused by the combined effects of congenital and acquired factors, comprising dietary habits. Several genetic variants have been proposed as co-factors in the pathogenesis of LRH with normal-low serum aldosterone. Emerging evidences support the hypothesis that a large proportion of LRH with normal-high serum aldosterone is associated with subclinical primary aldosteronism (PA). The recent identification of aldosterone-producing cell clusters (APCCs) as the possible cause of subclinical PA, further supported the concept of a continuous spectrum of autonomous aldosterone secretion, from subclinical forms towards overt PA. In this review we describe the main aspects of LRH, focusing on molecular basis, clinical risk profile and patients’ management.

The spectrum of low-renin hypertension

Buffolo F.
First
;
Monticone S.;Pecori A.;Pieroni J.;Losano I.;Cavaglia G.;Tetti M.;Veglio F.;Mulatero P.
Last
2020

Abstract

Low-renin hypertension (LRH) is a frequent condition in patients with arterial hypertension, accounting for 30% of patients. Monogenic forms can cause LRH in a minority of cases. However, in the large majority of patients, LRH is caused by the combined effects of congenital and acquired factors, comprising dietary habits. Several genetic variants have been proposed as co-factors in the pathogenesis of LRH with normal-low serum aldosterone. Emerging evidences support the hypothesis that a large proportion of LRH with normal-high serum aldosterone is associated with subclinical primary aldosteronism (PA). The recent identification of aldosterone-producing cell clusters (APCCs) as the possible cause of subclinical PA, further supported the concept of a continuous spectrum of autonomous aldosterone secretion, from subclinical forms towards overt PA. In this review we describe the main aspects of LRH, focusing on molecular basis, clinical risk profile and patients’ management.
101399
101405
aldosterone producing adenoma; aldosterone producing cells cluster; low renin hypertension; primary aldosteronism
Buffolo F.; Monticone S.; Pecori A.; Pieroni J.; Losano I.; Cavaglia G.; Tetti M.; Veglio F.; Mulatero P.
File in questo prodotto:
File Dimensione Formato  
Best Pract Res Clin Endocrinol Metab 2020 - 2nd submission.docx

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 132.98 kB
Formato Microsoft Word XML
132.98 kB Microsoft Word XML   Visualizza/Apri   Richiedi una copia
Figure 1 rev Best Pract.tif

Accesso aperto con embargo fino al 29/06/2020

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 4.98 MB
Formato TIFF
4.98 MB TIFF Visualizza/Apri
Best Pract Res Clin Endocrinol Metab 2020 - 2nd submission.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 318.65 kB
Formato Adobe PDF
318.65 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1742439
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact